{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:21:08Z","timestamp":1778502068527,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.intimp.2024.112955","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T18:11:19Z","timestamp":1724177479000},"page":"112955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Capecitabine mitigates cardiac allograft rejection via inhibition of TYMS-Mediated Th1 differentiation in mice"],"prefix":"10.1016","volume":"141","author":[{"given":"Dejun","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeqi","family":"Nian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiashu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinliang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuolun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-7084","authenticated-orcid":false,"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2024.112955_b0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.intimp.2024.112955_b0010","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.jacc.2010.12.030","article-title":"Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation","volume":"57","author":"von Vietinghoff","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112955_b0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.kint.2018.08.038","article-title":"mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases","volume":"95","author":"Johnson","year":"2019","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.intimp.2024.112955_b0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43587-023-00416-y","article-title":"Targeting the biology of aging with mTOR inhibitors","volume":"3","author":"Mannick","year":"2023","journal-title":"Nat. Aging."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-023-01820-z","article-title":"Expression of mTOR in normal and pathological conditions","volume":"22","author":"Marques-Ramos","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2024.112955_b0030","article-title":"Capecitabine can induce T cell apoptosis: a potential immunosuppressive agent with anti-cancer effect","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2011.06.040","article-title":"Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer","volume":"48","author":"Fedele","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0040","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1038\/s41598-017-11810-z","article-title":"The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation","volume":"7","author":"Ravaioli","year":"2017","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.intimp.2024.112955_b0045","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.3748\/wjg.v29.i20.3084","article-title":"Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients' T cell ferroptosis","volume":"29","author":"Wang","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.intimp.2024.112955_b0050","article-title":"ERK Inhibition promotes engraftment of allografts by reprogramming T-Cell Metabolism","volume":"10","author":"Tan","year":"2023","journal-title":"Adv. Sci. (Weinh)."},{"issue":"14","key":"10.1016\/j.intimp.2024.112955_b0055","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.7150\/thno.75543","article-title":"Single-Cell RNA sequencing reveals immune cell dynamics and local intercellular communication in acute murine cardiac allograft rejection","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics."},{"key":"10.1016\/j.intimp.2024.112955_b0060","first-page":"9794235","article-title":"Helper T Cell (CD4(+)) targeted tacrolimus delivery mediates precise suppression of allogeneic humoral immunity","volume":"2022","author":"Shen","year":"2022","journal-title":"Research (wash Dc)."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/imr.12038","article-title":"CD4(+) T-cell subsets in transplantation","volume":"252","author":"Liu","year":"2013","journal-title":"Immunol. Rev."},{"issue":"16","key":"10.1016\/j.intimp.2024.112955_b0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160579","article-title":"Treg suppression of immunity within inflamed allogeneic grafts","volume":"7","author":"Dai","year":"2022","journal-title":"JCI Insight."},{"issue":"12","key":"10.1016\/j.intimp.2024.112955_b0075","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1111\/ajt.12466","article-title":"IFN-\u03b3 blocks CD4+CD25+ Tregs and abolishes immune privilege of minor histocompatibility mismatched corneal allografts","volume":"13","author":"Cunnusamy","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"14","key":"10.1016\/j.intimp.2024.112955_b0080","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/jcmm.17799","article-title":"Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC","volume":"27","author":"Chen","year":"2023","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112955_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112955_b0090","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.4049\/jimmunol.171.7.3823","article-title":"Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting","volume":"171","author":"Wang","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112955_b0095","first-page":"1012509","article-title":"Capecitabine Regulates HSP90AB1 Expression and Induces Apoptosis via Akt\/SMARCC1\/AP-1\/ROS Axis in T Cells","volume":"2022","author":"Zhang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.intimp.2024.112955_b0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/sctm.20-0154","article-title":"CD73 expression is critical to therapeutic effects of human endometrial regenerative cells in inhibition of cardiac allograft rejection in mice","volume":"10","author":"Hu","year":"2021","journal-title":"Stem Cells Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13287-022-02982-1","article-title":"IL-37 overexpression promotes endometrial regenerative cell-mediated inhibition of cardiac allograft rejection","volume":"13","author":"Qin","year":"2022","journal-title":"Stem. Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0110","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1038\/s41467-023-40439-y","article-title":"Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy","volume":"14","author":"Lang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.112955_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2016.08.001","article-title":"The role of pharmacogenetics in capecitabine efficacy and toxicity","volume":"50","author":"Lam","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2024.112955_b0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1159\/000518297","article-title":"Phase II trial of the combination of temsirolimus and sorafenib in advanced hepatocellular carcinoma with tumor mutation profiling","volume":"10","author":"Kelley","year":"2021","journal-title":"Liver Cancer."},{"issue":"2","key":"10.1016\/j.intimp.2024.112955_b0125","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/ajco.13777","article-title":"Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses","volume":"19","author":"Xiang","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"10127","key":"10.1016\/j.intimp.2024.112955_b0130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.112955_b0135","doi-asserted-by":"crossref","first-page":"e232932","DOI":"10.1001\/jamasurg.2023.2932","article-title":"Long-term survival, prognostic factors, and selection of patients with colorectal cancer for liver transplant: a nonrandomized controlled trial","author":"Dueland","year":"2023","journal-title":"JAMA Surg."},{"key":"10.1016\/j.intimp.2024.112955_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation","author":"Norman","year":"2023","journal-title":"J. Hepatol."},{"issue":"1 Suppl","key":"10.1016\/j.intimp.2024.112955_b0145","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1097\/01.tp.0000186912.23630.85","article-title":"mTOR inhibition and its effect on cancer in transplantation","volume":"80","author":"Andrassy","year":"2005","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1432-2277.2004.00026.x","article-title":"Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer","volume":"18","author":"Guba","year":"2005","journal-title":"Transpl. Int."},{"issue":"12","key":"10.1016\/j.intimp.2024.112955_b0155","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.TP.0000120181.89206.54","article-title":"Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation","volume":"77","author":"Guba","year":"2004","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.intimp.2024.112955_b0160","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00007890-200405150-00002","article-title":"Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice","volume":"77","author":"Koehl","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.intimp.2024.112955_b0165","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jhep.2020.07.036","article-title":"p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma","volume":"74","author":"Luo","year":"2021","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112955_b0175","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/blood-2010-10-313684","article-title":"Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells","volume":"118","author":"Shin","year":"2011","journal-title":"Blood"},{"issue":"7977","key":"10.1016\/j.intimp.2024.112955_b0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41586-023-06483-w","article-title":"Metabolic programs of T cell tissue residency empower tumour immunity","volume":"621","author":"Reina-Campos","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.intimp.2024.112955_b0185","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/cvr\/cvad029","article-title":"Inhibition of phosphoglycerate kinase 1 attenuates autoimmune myocarditis by reprogramming CD4+ T cell metabolism","volume":"119","author":"Lu","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112955_b0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.immuni.2021.10.011","article-title":"MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function","volume":"55","author":"Sugiura","year":"2022","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.intimp.2024.112955_b0195","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/CM9.0000000000001866","article-title":"A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients","volume":"135","author":"Zheng","year":"2022","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"9","key":"10.1016\/j.intimp.2024.112955_b0200","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.intimp.2024.112955_b0205","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","author":"Toso","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112955_b0210","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","article-title":"Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer","volume":"14","author":"Manegold","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112955_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114232","article-title":"Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD","volume":"159","author":"de With","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"21","key":"10.1016\/j.intimp.2024.112955_b0220","doi-asserted-by":"crossref","first-page":"7856","DOI":"10.1039\/D2NR02064E","article-title":"Reverse anti-breast cancer drug resistance effects by a novel two-step assembled nano-celastrol medicine","volume":"14","author":"Xiao","year":"2022","journal-title":"Nanoscale"},{"issue":"26","key":"10.1016\/j.intimp.2024.112955_b0225","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1039\/C8NR02700E","article-title":"Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance","volume":"10","author":"Xiao","year":"2018","journal-title":"Nanoscale"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924014760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924014760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:36:22Z","timestamp":1731087382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924014760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":45,"alternative-id":["S1567576924014760"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112955","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capecitabine mitigates cardiac allograft rejection via inhibition of TYMS-Mediated Th1 differentiation in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112955"}}